Related Experiment Videos
An episomally maintained MDR1 gene for gene therapy
C G Lee1, W D Vieira, I Pastan
1Department of Biochemistry, National University of Singapore, Singapore.
Human Gene Therapy
|June 2, 2001
Summary
This study demonstrates that nonviral MDR1 gene delivery using an episomal vector (pEpiHaMA) can protect cells from chemotherapy drugs. This method offers a safer alternative to viral gene therapy for cancer treatment.
Area of Science:
- Gene Therapy
- Molecular Biology
- Cancer Research
Background:
- The MDR1 gene transporter has potential in gene therapy for cancer chemotherapy.
- Viral gene delivery systems raise safety concerns due to integration risks.
Purpose of the Study:
- To evaluate the feasibility of nonviral, episomal maintenance of the MDR1 gene.
- To assess the safety and efficacy of episomal MDR1 gene delivery as an alternative to viral methods.
Main Methods:
- Transfection of human cells (KB-3-1) with an MDR1 episomal vector (pEpiHaMA) containing EBV OriP and EBNA-1.
- Comparison of MDR1 expression and drug resistance with a non-episomal vector (pHaMA).
- In vivo studies using tumor explants in nude mice injected with pEpiHaMA-liposome complexes.
Main Results:
- Higher MDR1 expression was observed with the episomal pEpiHaMA vector.
- Increased drug-resistant colonies were obtained after transfection with pEpiHaMA.
- Episomes were maintained extrachromosomally for over a month in vivo.
Conclusions:
- Nonviral episomal delivery of the MDR1 gene is feasible and effective.
- Episomal MDR1 vectors offer a potentially safer approach for gene therapy applications.
- Extrachromosomal maintenance of MDR1 in vivo supports its use in therapeutic strategies.